Senti Biosciences clears $2M third-tranche note sale to NSG
Senti Biosciences amended its Securities Purchase Agreement on September 1, 2026 to permit senior secured convertible notes in more than two tranches, authorizing a $2.0 million third-tranche issuance to NSG BioInnovation Fund with CPIF II-7 consent.
Senti Biosciences amended its Securities Purchase Agreement on September 1, 2026, allowing Senior Secured Convertible Notes to be issued in more than two tranches and specifically authorizing a $2.0 million third-tranche issuance to NSG BioInnovation Fund. With CPIF II-7’s consent, the NSG purchase was permitted under the revised terms.